New dialysis fluid may slow hardening of arteries in kidney patients
NCT ID NCT07163936
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a citrate-based dialysis fluid with extra magnesium can slow or prevent blood vessel hardening in adults on long-term hemodialysis. Eighty stable patients will receive either the new fluid or a standard one for 12 months. Researchers will measure blood markers of calcification risk and monitor heart problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- citrate-based dialysate with magnesium
- What this could lead to
- If it works, this could point toward a safer dialysis fluid that reduces heart problems and death in kidney patients.
- What could go wrong
- This is a small, early-stage study with only 80 participants, so results may not apply to everyone. The intervention only changes the dialysis fluid, so any benefit is likely modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE (CKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can video games and electric pulses ease dialysis Patients' shoulder pain?
- Dialysis danger: a new model aims to predict sudden blood pressure crashes
- A helping hand for dialysis: can coaching reduce the emotional toll?
- A simple blood pressure cuff trick could shield the heart in kidney disease
- Could cutting dialysis sessions in half improve life for seniors?
- Teaching dialysis patients to take control: can a Four-Week Nurse-Led program improve diet and Self-Care?